Isocitrate Dehydrogenase Inhibitors
Market
Isocitrate Dehydrogenase Inhibitors Market Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Isocitrate Dehydrogenase Inhibitors Market Size and Growth
The Isocitrate Dehydrogenase Inhibitors market is poised for substantial growth, driven by rising cancer incidences and increasing R&D investments. The market size is projected to reach approximately $1.5 billion by 2026, reflecting a CAGR of over 15%. Market conditions are favorable, with expanding clinical applications and innovative therapeutic developments.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ AGIOS
◍ Aslan Pharmaceuticals
◍ Bayer
◍ Beigene
◍ Bristol-Myers Squibb
◍ Celgene
◍ Daiichi Sankyo
◍ Philogen S.p.A.
◍ Tesaro
◍ Tragara/Adastra
◍ Tocagen
The Isocitrate Dehydrogenase Inhibitors Market features companies like AGIOS, Bayer, and Bristol-Myers Squibb, focusing on targeted therapies for cancer. They contribute to market growth through innovative drug development, collaborations, and expanding indications.
Notable revenues include:
- AGIOS: ~$270 million (2022)
- Bayer: ~$49 billion (2022)
- Bristol-Myers Squibb: ~$46 billion (2022) Request Sample Report
Market Segmentation
By Application
DH Inhibitor
FLT3 Inhibitor ◍ Hedgehog Pathway Inhibitor ◍ Others
By
Product
◍ IDH1 Mutant Medullary Malignant Tumor
IDH2 Mutant Medullary Malignant Tumor
Others
Request Sample Report
Market Growth
Request Sample Report
$ 1.72 Billion
